Vion Pharmaceuticals (VION) Announces Results of the Oncologic Drugs Advisory Committee
9/2/2009 11:00:34 AM
NEW HAVEN, Conn., Sept. 2 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC.
(OTC Bulletin Board: VION) today announced the results of the Oncologic Drugs
Advisory Committee (ODAC) Meeting at which data for its lead oncology
therapeutic Onrigin(TM)(laromustine) Injection were presented for the
indication of remission induction treatment for patients sixty years of age or
older with de novo poor-risk acute myeloid leukemia (AML).
comments powered by